Vitrolife Group
October 22, 2026
Vitrolife Group reported third-quarter sales of SEK 884 (835) million, corresponding to organic growth of 6% in local currencies excluding the exited NACE and GPDx product lines, with Technologies up 21% and EMEA up 11%. EBITDA rose to SEK 279 (253) million, a margin of 31.6% (30.3), while net income increased to SEK 124 (102) million, or SEK 0.94 (0.75) per share. Operating cash flow was SEK 224 (255) million, and the company repurchased own shares for SEK 246 million under its SEK 500 million programme. This summary was AI-generated.
Source:
Vitrolife Group